

# 1 **The Effect of Intradialytic Exercise on Calcium, Phosphorus** 2 **and Parathyroid Hormone: A Randomized Controlled Trial**

3  
4 Mohammadali Tabibi\*<sup>1</sup>, Kenneth R Wilund<sup>2</sup>, Nasrin Salimian<sup>3</sup>, Saghar Nikbakht<sup>4</sup>, Mahsa

5 Soleymany<sup>5</sup>, Zahra Roshanaeian<sup>6</sup>, Saghar Ahmadi<sup>7</sup>

6  
7 <sup>1</sup>Department of Exercise Physiology, Pardis Specialized Wellness Institute, Isfahan, Iran

8 <sup>2</sup>Department of Kinesiology and Community Health, Division of Nutritional Sciences,

9 University of Illinois at Urbana-Champaign, USA.

10 <sup>3</sup>Department of Statistics and Community Development, Pardis Specialized Wellness Institute,

11 Isfahan, Iran

12 <sup>4</sup>Department of Kinsiology, Pardis Specialized Wellness Institute, Isfahan, Iran

13 <sup>5</sup>Department of Exercise Physiology, Pardis Specialized Wellness Institute, Isfahan, Iran

14 <sup>3</sup>Department of Sport Nutrition, Pardis Specialized Wellness Institute, Isfahan, Iran

15 <sup>7</sup>Department of Health and Palliative Care, Pardis Specialized Wellness Institute, Isfahan, Iran

16

17 **Short Title:** Exercise in HD RCT

18 **Address for Correspondence:**

19 MohammadAli Tabibi

20 No32, Arbab St, Isfahan, Iran.

21 Phone: +989132051202, +983135229060

22 Fax: +983135229060

23 Email: m.tabibi@ut.ac.ir

24

25 **Abstract**

26 **Introduction**

27 Patients with kidney failure experience derangements of circulating markers of mineral  
28 metabolism and dysregulation of skeletal and cardiovascular physiology which results in high  
29 mortality rate in these patients. This study aimed to evaluate the effect of intradialytic concurrent  
30 exercise on regulation of these abnormalities related parameters in patients receiving  
31 hemodialysis (HD).

32 **Methods**

33 In this randomized controlled trial conducted in a HD center in Iran, adult patients receiving  
34 chronic HD were randomized to intradialytic exercise (60 minutes) in the second hour of thrice  
35 weekly dialysis for 6 months (intervention) or no intradialytic exercise (control). The primary  
36 outcomes were serum calcium, serum phosphorous and parathyroid hormone levels. Secondary  
37 outcomes were serum alkaline phosphatase and calcium-phosphorous product

## 38 **Results**

39 The study included 44 participants randomized to intervention (n=22) or control (n=22). During  
40 the 6-month intervention period, significant between-group changes were observed in all primary  
41 and secondary outcomes between the intervention and control groups. The analysis showed a  
42 significant decrease in serum levels of phosphorous and parathyroid hormone ( $P < 0.05$ ).  
43 Statistical analyses reveal a significant increase in serum calcium ( $P < 0.05$ ) as well as a  
44 significant decrease in serum phosphorous, parathyroid hormone, alkaline phosphatase and  
45 calcium-phosphorous product ( $P < 0.05$ ).

46

## 47 **Conclusion**

48 Intradialytic exercise performed for at least 60 minutes during thrice weekly dialysis sessions  
49 improves bone mineral metabolism in adult patients receiving HD. Further studies should focus  
50 on observing the effect of different types of exercise on bone mineral disorders and all-cause  
51 mortality in HD patients.

52

## 53 **Trial registration**

54 ClinicalTrials.gov Identifier: NCT04916743, Registered on June 8th,2021. Registered trial name:  
55 The Effect of Intradialytic Exercise on Calcium, Phosphorous and Parathyroid Hormone: A  
56 Randomized Controlled Trial

57 **Key words:** Mortality, Exercise during dialysis, Bone mineral disorders, Cardiovascular disease,  
58 Hematological Parameters

59

## 60 **Introduction**

61           In recent years, there has been a rapid increase in the prevalence of patients with end stage  
62 kidney disease (ESKD) that require kidney replacement therapy, including hemodialysis (HD),  
63 peritoneal dialysis (PD) or kidney transplant [1]. ESKD patients, especially those on HD and PD,  
64 experience high rates of functional impairment, morbidity, hospitalization, and mortality [2, 3].  
65 These outcomes are an urgent priority for patients, caregivers and healthcare professionals [4, 5].  
66 The primary etiological factors responsible for these outcomes include cardiovascular disorders,  
67 muscle atrophy and malnutrition [3]. Cardiovascular disease in ESKD patients is associated with  
68 traditional risk factors (diabetes, hypertension, sedentary lifestyle) as well as nontraditional factors  
69 (anemia, inflammation, abnormal calcium and phosphorus metabolism and oxidative stress) [6].  
70 High levels of calcium, phosphorus, calcium- phosphorus product and parathyroid hormone are  
71 associated with all causes of mortality in dialysis patients [7]. Hyperphosphatemia is also a  
72 common complication in ESKD. As renal excretion of phosphorus decreases, this results in  
73 increased serum levels of phosphorus and hyperphosphatemia. Calcium and parathyroid hormone  
74 are phosphorus-dependent. Hyperphosphatemia alone or in combination with hypercalcemia is  
75 associated with increased mortality in hemodialysis patients. Phosphate metabolism is regulated  
76 by the interaction of the kidneys, bones, and intestines. This balance is impaired in kidney patients,  
77 leading to hyperparathyroidism and vascular calcification [8].  
78 Hyperparathyroidism is one of the aggravating causes of anemia in hemodialysis patients, in  
79 addition to resistance to erythropoietin treatment. Defects in calcitriol synthesis, which along with  
80 parathyroid hormone stimulates calcium reabsorption, causes hypocalcemia and  
81 hyperphosphatemia in dialysis patients. In this condition, there is an increase in parathyroid

82 hormone synthesis to regulate calcium and phosphorus homeostasis, leading to secondary  
83 hyperparathyroidism [9-11].

84 Abnormal levels of parathyroid hormone are associated with disorders of the musculoskeletal  
85 system and decreased function, which can lead to increased mortality in these patients. Synthesis  
86 and the use of muscular energy are affected by elevated levels of this hormone, which in turn,  
87 causes interference in amino acids and protein metabolism in the musculoskeletal system. [12,13].  
88 In CKD patients, especially in chronic (dialysis) patients, the respiratory system is also affected  
89 because both uremia and high levels of parathyroid hormone endanger lung function [14].  
90 Therefore, dialysis patients have respiratory disorders and decreased aerobic capacity due to  
91 vitamin D deficiency [15] and high levels of parathyroid hormone [14]. Indeed, the functional  
92 capacity in dialysis patients has been shown to be about 50% of what it is in healthy populations  
93 [16].

94 The regulation of parathyroid hormone is critical for bone metabolism in healthy  
95 individuals as well as dialysis patients [17], and may be influenced by physical activity [18].  
96 Indeed, numerous studies in healthy individuals indicate that exercise plays an important role in  
97 the regulation of this hormone [17,19-22]. However, little is known about the role of exercise  
98 especially concurrent exercise on parathyroid hormone and calcium and phosphorus metabolism  
99 in dialysis patients.

100

## 101 **Methods**

### 102 **Trial design**

103 This study is an open-label, parallel arm, randomized controlled trial with blinded end-points,  
104 which was conducted in a medical center in Iran.

105

## 106 **Participants**

107 Individuals were eligible to participate in the study after meeting all of the following inclusion  
108 criteria: 1) age  $\geq$  18 years; 2) receiving regular HD 3 times a week; 3) on HD for at least 1 year,  
109 4) absence of a history of myocardial infarction within the past 3 months; 5) permission from  
110 their physician to participate; and, 6) had capacity to provide informed consent to participate in  
111 the study. Individuals were excluded if they met any of the following exclusion criteria: 1)  
112 cardiac instability (angina, decompensated congestive heart failure, severe arteriovenous  
113 stenosis, uncontrolled arrhythmias, etc.); 2) active infection or acute medical illness; 3)  
114 hemodynamic instability (systolic blood pressure  $<$  90 mmHg or mean arterial pressure  $<$  60  
115 mmHg); 4) labile glycemic control (extreme swings in blood glucose levels, causing  
116 hyperglycemia or hypoglycemia) ; 5) inability to exercise (e.g. lower extremity amputation with  
117 no prosthesis); 6) severe musculoskeletal pain at rest or with minimal activity; 7) inability to sit,  
118 stand or walk unassisted (walking device such as cane or walker allowed); or, 8) shortness of  
119 breath at rest or with activities of daily living (NYHA Class IV).

120

## 121 **Trial Procedures**

122 Before starting the study, some educational and motivational posters were installed in the  
123 dialysis center, so that all patients became familiar with the benefits of exercise and especially  
124 intradialytic exercise. Then principal investigator described the side-effects of inactivity and  
125 sedentary lifestyle to all patients. Specifically, the PI encouraged all patients to be active and

126 provided information regarding potential benefits of intradialytic exercise. After providing  
127 written informed consent, eligible patients received a baseline assessment. Data were collected  
128 on demographic characteristics (age, sex, and time on hemodialysis), primary cause of kidney  
129 failure, and comorbidities (atherosclerotic heart disease, congestive heart failure, cerebrovascular  
130 accident/transient ischemic attack, peripheral vascular disease, dysrhythmia, and other cardiac  
131 diseases, chronic obstructive pulmonary disease, gastrointestinal bleeding, liver disease, cancer,  
132 and diabetes). Comorbidities were quantified using Charlson comorbidity index (CCI)  
133 established for dialysis patients, which included the underlying cause of kidney failure, as well as  
134 11 comorbidities [14].

135 Participants were then randomized in a 1:1 ratio to either the intervention group or control group.  
136 The randomization sequence was generated by a study biostatistician who was not otherwise  
137 involved in the study using a computer-generated random schedule (using Stata 16, Stata Crop,  
138 College Station, Tx). Allocation concealment was safeguarded through the use of sequentially  
139 numbered, sealed, opaque envelopes by a specified staff member who was not involved in the  
140 study.

141

## 142 **Intervention**

143 Subjects in the intervention group performed concurrent intradialytic exercise during the 2nd hour  
144 of dialysis (60-minute exercise sessions three times a week) for 6 months. The intervention was a  
145 combination of aerobic and resistance exercises. Workout time at the beginning was 30 minutes  
146 and gradually increased to 60 minutes. Each workout session included 5 minutes of warm-up,  
147 aerobic exercises, resistance exercises and finally 10 minutes of stretching exercises to cool down.  
148 The fistula arm was kept stationary thoroughly the exercise session, with necessary precautions taken into  
149 consideration. Also, the exercise protocol was not performed on the arm with AV fistula.

150 Exercises were individualized in a way that matched the level of physical fitness of participants  
151 (See Additional File 1). Aerobic exercises consisted of continuously performed specified  
152 movements, such as moving legs back and forth, shoulder abduction and adduction (hand  
153 without fistula), flexing and extending the knee, internally and externally rotating the leg, and  
154 abducting and adducting the leg, in time with a played beat.

155 The rhythm of continuous movements was adjusted by the beats per minute of the music. This  
156 meant that participants had to coordinate the movements of their arms and legs with the beats per  
157 minute of the song being played to them. In this way, the speed and intensity of aerobic exercise  
158 was controlled by the rhythm. Resistance training was performed in a semi-recumbent position  
159 and included exercises for the upper and lower limbs as well as core strength exercises using  
160 body weight, weight cuffs, dumbbells, and elastic bands of varying intensity. Chest press,  
161 shoulder press, triceps extension, straight arm shoulder flexion, shoulder horizontal abduction,  
162 seated row, supine grip, prone grip, neutral grip, bicep curl, leg abduction, plantarflexion,  
163 dorsiflexion, straight-leg/bent knee raises, knee extension, and knee flexion were all part of the  
164 resistance training program.

165 All of the exercises were prescribed by an exercise physiologist who also monitored the exercise  
166 sessions and helped patients with any questions they had. At the end of each session, the exercise  
167 physiologist reviewed the adherence checklists. If a person did not attend an exercise session, a  
168 counseling session was held in the presence of a nephrologist and the exercise physiologist. The  
169 reason for the individual's non-participation was investigated and the positive effects of exercise  
170 was explained through motivational statements. When possible, patients were reminded of  
171 previous benefits of exercise they had experienced as an incentive for them to increase adherence  
172 with the training.



173

174 Participants in the control group did not undertake any specific physical activity during dialysis.

175 All other pharmacological, dialysis, dietary and management protocols were identical for

176 participants in both groups. Despite differences in some hematological parameters at baseline,

177 different medications were not used for intervention group. All participants received normal

178 bicarbonate hemodialysis, which was carried out three times a week for an average of 4 hours.

179 Volumetric ultrafiltration control was available on all machines. The standard dialysate flow rate

180 was 500 mL/min and blood flow rates were prescribed according to the participant's needs.

181 Automated methods were applied to perform dialyzer reuse uniformly.

182

### 183 **Blood sampling**

184 Baseline blood samples were collected one day before the start of the exercise session. Exercise

185 began at the mid-week dialysis session. After the end of the 36th session (end of the third month)

186 and after the end of the 72nd session (end of the sixth month), subsequent blood samples were

187 collected the day before the midweek dialysis session. The control group was assessed at the

188 same time points. On a nondialysis day, blood samples were taken from the arterial needle after

189 at least an 8-hour fast. Approximately 30 milliliters of blood were collected and centrifuged for

190 15 minutes at 20 °C and 2500 g. Plasma was next pipetted into cryotubes and stored at -80 °C in

191 a freezer that was electronically monitored. All samples were measured in duplicate, in line with

192 the manufacturers' suggested protocol, and within the manufacturer's specified range of

193 acceptable variation and sensitivity.

194

### 195 **Outcomes**

196 The primary outcome measures included changes in serum calcium (mg/dL), serum phosphorous  
197 (mEq/L) and parathyroid hormone (pg/mL) over time. Rate of changes of alkaline phosphatase  
198 (U/L) and calcium-phosphorous product ( $\text{mg}^2/\text{dL}^2$ ) were the secondaries. These outcomes were  
199 evaluated at baseline, 3 months and 6 months.

200 Safety outcomes included all serious adverse events and adverse events.

### 201 **Adherence**

202 Intervention adherence was defined as the number of sessions performed divided by the number  
203 of sessions offered, multiplied by 100.

204

### 205 **Blinding**

206 Due to the nature of the intervention, it was not feasible to blind participants or study staff.

207 However, outcome assessors and data analysts were blinded to participants' treatment  
208 allocations.

### 209 **Sample size**

210 The sample size was calculated in accordance with a previous study [23], by NCSS PASS 16.0  
211 software. The model was established according to the Repeated Measure ANOVA (bilateral  
212 side) for the PTH as main variable, with  $\alpha=0.05$  and power  $1 - \beta = 0.8$ .

213 Assuming an effect size of 0.45 for reduction of PTH and a drop-out rate of 20%, 44 participants  
214 (22 per group) were required to provide 80% power.

### 215 **Statistical analysis**


216 Data are presented as frequency (percentage), mean  $\pm$  standard deviation, or median and  
217 interquartile range, depending on data type and distribution. A detailed statistical analysis plan  
218 was prepared and completed prior to database lock. Primary and secondary outcomes were

219 evaluated using Repeated Measure ANOVA and the Friedman test. Statistical analyses were  
220 performed using IBM SPSS software 25. P values less than 0.05 were considered statistically  
221 significant.

## 222 Results

223 Overall, 58 patients were assessed for eligibility, of whom 44 were consented and randomized.

224 The corresponding flowchart is presented in Figure 1.



225

226 **Figure 1.** Participant flow during the study.

227 During the 6-month intervention period, 2 participants in the intervention group and 3

228 participants in the control group dropped out of the study.

229

230 **Baseline characteristics**

231 Baseline characteristics were balanced between the assigned treatment groups (Table 1).

**Table1.** Baseline characteristics of patients

	Intervention (n=22)	Usual Care (n=22)
Sex Male	13 (59%)	15 (68%)
Age (year)	61 ± 14	63 ± 11
Hemodialysis history (months)	29 ± 10	25 ± 9
Primary kidney disease		
Diabetes	5 (23%)	3 (14%)
Hypertension	8 (36%)	9 (41%)
Glomerulonephritis	6 (27%)	8 (36%)
Other	3 (14%)	3 (9%)
CCI	6.5 ± 2.3	7 ± 2

Values are as mean (standard deviation) or n (%)

CCI Charlson Comorbidity Index

232 The adherence rate was 78.5% ± 5%.

233 **Outcome analysis**

234 Significant between-group changes during the 6-month intervention period were observed in all  
235 primary and secondary outcomes (Table 3) between the intervention and control groups.

236 Specifically, serum calcium tended to increase in the intervention group, but remained relatively

237 stable in the control group. In contrast, serum parathyroid hormone, phosphorus, calcium-

238 phosphorous product and alkaline phosphatase levels significantly decreased in the intervention  
 239 group but remained relatively stable in the control group (Table 3).

240 **Safety**

241 No treatment-related serious adverse effects were observed during the period of the study.  
 242 During the intervention period, one patient had muscle cramps after the first exercise session, but  
 243 this was not serious or harmful.

**Table 3.** Change of primary and secondary outcomes and the results of longitudinal analysis

	Intervention			Usual care			Partial Eta Square	Group ×Time
	Baseline (n=22)	3 months (n=22)	6 months (n=20)	Baseline (n=22)	3 months (n=21)	6 months (n=19)		
Ca (mg/dl)	8.1 ± 0.8	8.7 ± 0.6	9.2 ± 0.6	8.4 ± 0.7	8.6 ± 0.7	8.5 ± 0.6	0.5	<0.001**
P (meq/lit)	5.8 ± 1.4	5.1 ± 1.1	4.1 ± 0.5	5.4 ± 1.3	5.9 ± 1.2	5.3 ± 0.9	0.4	0.002**
PTH (pg/ml)	441 (364 - 597)	290 (224 - 391)	245 † (173 - 286)	270 (180 - 418)	342 (245 - 476)	312 (243 - 407)	0.8	NA
Ca × P (mg <sup>2</sup> /dL <sup>2</sup> )	45.5 ± 4.6	43 ± 5.1	35.9 ± 4.1	43.8 ± 5.5	50.5 ± 4.9	44.2 ± 5	0.5	0.04*
ALP (U/L)	195.5 ± 8.6	148 ± 5.5	125.4 ± 7.9	203.5 ± 7.8	221.1 ± 8.3	211 ± 10.5	0.9	<0.001**

Ca serum calcium, P serum phosphorous, PTH parathyroid hormone, ALP alkaline phosphatase

Values are as mean ± standard deviation or median (interquartile)

Group ×Time is an interaction from a two-way repeated-measures analysis of the effect of time from baseline to 6 months

\*p < 0.05 significant

\*\*p < 0.01 highly significant

†p < 0.01 highly significant within-group difference, analyzed by Friedman test

244

245

## 246 **Discussion**

247 Renal hyperparathyroidism is a common complication of chronic kidney disease characterized  
248 by elevated PTH levels secondary to derangements in the homeostasis of calcium, phosphate,  
249 and vitamin D [24].

250 Abnormalities in calcium, phosphorous, and PTH, hallmarks of the condition known as chronic  
251 kidney disease – mineral and bone disorder (CKD-MBD) [25], are associated with adverse  
252 outcomes in patients receiving maintenance dialysis [7,8,26]. In patients with advanced chronic  
253 kidney disease results in derangements of circulating markers of mineral metabolism and in  
254 dysregulation of skeletal and cardiovascular physiology [27-29]. Epidemiologic studies of  
255 dialysis patients provide substantial evidence that elevated PTH is associated with mortality  
256 [8,26]. However, therapies targeting abnormal CKD-MBD parameters, while improving  
257 biochemical end points [30], have failed to convincingly demonstrate reductions in “hard” end  
258 points such as all-cause and cardiovascular mortality in clinical trials [31]. The Kidney Disease  
259 Improving Global Outcomes guidelines recommend that screening and management of  
260 hyperparathyroidism be initiated for all patients with chronic kidney disease [25].

261 The present study demonstrated that the 6-month intradialytic concurrent exercise program was  
262 effective in improving PTH levels, reducing serum phosphorous and improving serum calcium  
263 and calcium-phosphorous product as well. However, contradictory results have been reported by  
264 some other studies.

265 Previous work showed that exercise decreased plasma PTH levels in CKD patients [32].

266 Research on effect of exercise on PTH is limited, but it is affected by physical activity. Its levels

267 can vary after physical exercise depending on the duration and intensity of the activity [33].

268 Moreover, resistance to PTH action can occur with progression of renal disease [34].

269 In the present study, phosphorus levels in the intervention group were significantly lower than  
270 the baseline. The effect of exercise on phosphorus level was in line with findings of the several  
271 previous studies [35,36]. Borzou et al. also reported that increasing the blood flow to 250  
272 mL/min and then to 300 mL/ min can be effective in clearance of phosphorus from the blood  
273 [36].

274 Reviewing the limited available research on the effects of exercise in reducing phosphorus levels  
275 showed that although exercise decreased the level of phosphorus, the significant effects and  
276 changes could be observed in long-term and perhaps more intense exercise might be required for  
277 some studies [35,37,38].

278 This study revealed that serum calcium levels showed significant change in the intervention  
279 group but Saralhab et al. like some other researchers failed to retrieve any influence of exercise  
280 on serum calcium [24,34,39]. Perhaps studies with longer time frame and differences in type and  
281 frequency of exercise are needed.

282 Cardoso et al. in their systemic review found evidence supporting a positive relation between  
283 physical activity and bone outcomes in patients with CKD [40]. Studies show that exercise acts  
284 as a regulator of homeostasis, alters the levels of circulatory mediators and hormones, and  
285 increases the demand for skeletal muscle and other vital organs for energy substrates. Exercise  
286 also activates bone and mineral metabolism, especially calcium and phosphate, both of which are  
287 essential for muscle contraction, neuromuscular signaling, adenosine triphosphate biosynthesis,  
288 and other energy substrates. Due to the fact that PHT is involved in the regulation of calcium and

289 phosphate homeostasis, chronic exercise may help in limiting PTH secretion exercise activity by  
290 changing the level of calcium and phosphate in the bloodstream. On the other hand, PTH reacts  
291 directly to exercise and exercise myokines. [33].

292 Alkaline phosphatase is an enzyme measurable in most body fluids and usually originates from  
293 the liver or bone. In CKD patients without liver disease, ALP is a surrogate of high turnover  
294 bone disease and is used to monitor the metabolic bone disease associated with renal  
295 insufficiency [41-43]. Furthermore, elevated ALP may be causally involved in the cardiovascular  
296 calcification of CKD [44-46], making it a potentially important independent risk factor. Higher  
297 ALP has been shown to be associated with mortality and coronary artery calcification in CKD  
298 5D [43] and in patients without CKD [47]. In CKD, ALP is more reliable than many other  
299 biochemical bone markers because serum concentrations of ALP are not influenced by the  
300 glomerular filtration rate [47]. An association exists between higher serum ALP and worse dual-  
301 energy X-ray absorptiometry-assessed BMD in HD patients [48].

302 ALP levels significantly decreased in exercise group, but controls showed no similar change.

303 Previous observational studies on dialysis patients revealed a relationship between physical  
304 activity serum levels of ALP due to the fact that energy expenditure has a strong relationship to  
305 the total BMD [49,50].

306 The study by Gomes et al. and the other one by Elshinnawy et al. showed there was significant  
307 increase in ALP levels following exercise in patients with CKD [24,51].

308 One of the reasons for the contradiction in the process of ALP changes with the previous studies  
309 is that in those studies, the ALP level of the patients was within the normal range before the  
310 intervention, and the intervention has somehow improved the condition. However, in the current



311 study, the ALP level of the patients was much higher than normal, and exercise has been able to  
312 have a significant positive effect on improving the patients' condition by reducing the ALP level.

313 As levels of bone specific ALP increase during weight-bearing exercise [52], but return to  
314 baseline within 20-minutes following exercise, lower resting levels may be a consequence of the  
315 transient response to weight bearing exercises [53].

316 Based on Mechanostat theory which was developed by Harold frost, the local deformation from  
317 the mechanical loading stimulates bone cells and results in bone adaptation (it means that bone  
318 tissues accommodate to the stress applied on it) [54, 55]. Without any doubt bones are subjected  
319 to two sources of load including ground reaction force and muscular force [54].

320 High proinflammatory cytokine levels may contribute to bone loss and fracture in patients with  
321 CKD [51]. In addition, inflammatory cytokines are potent activators of receptor activator of  
322 nuclear factor kappa B ligand / receptor activator of nuclear factor kappa B (RANKL/RANK)-  
323 activated osteoclast genesis [55]. Exercise may inactivate the RANKL/RANK pathway by  
324 ameliorating inflammation and preventing bone loss in HD patients.

325 A major strength of the present study was the fact that all exercises were tailored according to  
326 each individual's functional status within a pre-specified structure. There was also a high  
327 participation rate, such that included HD patients exhibited considerable diversity with respect to  
328 demographic characteristics and associated comorbidities. In this study also, is that, at the end of  
329 the study, the level of calcium, phosphorus and parathyroid hormone in the intervention group  
330 reached the level recommended by KDOQI guidelines [25].

331 This discrepancy between the results of the present study and the findings of the above-  
332 mentioned studies can be attributed to differences in participants' age and sex or duration,

333 intensity, and type of exercise program. The length of the other studies is shorter. Moreover, the  
334 intradialytic intervention was performed as concurrent exercise which was different from other  
335 studies, performing only resistance or aerobic exercise.

336 Balanced against these strengths, the study also had a number of limitations. Not measuring the  
337 effect of exercise on bone mass and cardiovascular indexes are limitations of this study. Indeed,  
338 not measuring bone mineral density in this work is a limitation as bone strength depends on bone  
339 quality and quantity. Future work should focus on observing the effect of different types of exercise  
340 on bone mineral disorders and all-cause mortality in HD patients.

## 341 **Conclusion**

342 Intradialytic exercise performed for at least 60 minutes during thrice weekly dialysis sessions  
343 improves bone mineral metabolism in adult patients receiving HD and perhaps decrease all-cause  
344 mortality in these patients. Further studies should focus on observing the effect of different types  
345 of exercise on bone mineral disorders and all-cause mortality in HD patients.

## 346 **Declaration**

347 Ethics approval and consent to participate

348 The study protocol and informed consent were approved by Iran National Committee for Ethics  
349 in Biomedical Research (approval number IR.IAU.KHUISF.REC.1400.088) and was conducted  
350 in accordance with principles of the Declaration of Helsinki. All patients provided written  
351 informed consent prior to enrollment.

## 352 **Consent for publication**

353 Not applicable

354 **Competing interest**

355 The authors declare that they have no competing interest.

356 **Funding**

357 Not applicable

358 **Authors' Contribution**

359 MAT: conceptualizing the study, project leader of the study, conducting the study, writing of the  
360 manuscript, supervising of the analysis, interpreting the results, approval of the manuscript, KW:  
361 conceptualizing of the study, co-writing of the manuscript, supervising of the manuscript,  
362 approval of the manuscript, NS: project leader of the study, analyzing the data, interpreting the  
363 results, co-writing of the manuscript, approval of the manuscript, SN: conceptualizing the study,  
364 conducting the study, co-writing of the manuscript, supervising of the manuscript, approval of  
365 the manuscript, MS: conceptualizing the study, conducting the study, co-writing of the  
366 manuscript, supervising of the manuscript, approval of the manuscript, ZR: conceptualizing the  
367 study, conducting the study, co-writing of the manuscript, supervising of the manuscript,  
368 approval of the manuscript, SA: conceptualizing the study, conducting the study, co-writing of  
369 the manuscript, approval of the manuscript. Each author contributed with important intellectual  
370 content during the manuscript drafting or revision and accepts accountability for the overall work  
371 by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are  
372 appropriately investigated and resolved. All authors read and approved the final manuscript.

373

374 **Acknowledgement**

375 The authors would like to express their heart-felt gratitude to all the investigators for their  
376 contribution to the trial, especially Dr. Hugo Corrêa and Dr. João and all the staff of the dialysis  
377 center for their efforts and patience in helping to maintain the standards of the research, as well  
378 as all patients involved in this study. Also, the authors would like to thank Pardis Specialized  
379 Wellness Institute and all the personnel of the institute for their support throughout the study.  
380 The authors would also like to thank the opportunity that medRxiv offered them to deposit the  
381 preprint version.

382 .

383

384

## 385 **References**

- 386 1. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, et al. Epidemiology,  
387 contributors to, and clinical trials of mortality risk in chronic kidney failure. *Lancet*.  
388 2014;383(9931):1831–43
- 389 2. United States Renal Data System. Epidemiology of kidney disease in the United States.  
390 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney  
391 Diseases, Bethesda, MD, 2018. Available at  
392 <https://www.usrds.org/2018/view/Default.aspx>.
- 393 3. Deligiannis A, D'Alessandro C, Cupisti A. Exercise training in dialysis patients: impact  
394 on cardiovascular and skeletal muscle health. *Clin Kidney J*. 2021 Jan 11;14(Suppl  
395 2):ii25-ii33. doi: 10.1093/ckj/sfaa273. PMID: 33981417; PMCID: PMC8101623.

- 396 4. SONG Initiative. The SONG Handbook. Version 1.0 June 2017, Sydney,Australia  
397 Available at [songinitiative.org/reports-and-publications/](http://songinitiative.org/reports-and-publications/).
- 398 5. Manera KE, Tong A, Craig JC, Shen J, Jesudason S, Cho Y, et al. An international  
399 Delphi survey helped develop consensus-based core outcome domains for trials in  
400 peritoneal dialysis. *Kidney Int.* 2019;96(3):699–710.
- 401 6. D. S. March, M. P. M. Graham-Brown, C. M. Stover, N. C. Bishop, and J. O. Burton,  
402 “Intestinal Barrier sturbances in Haemodialysis Patients: Mechanisms, Consequences,  
403 and Therapeutic Options,” *BioMed Research International*, vol. 2017, Article ID  
404 5765417, 2017.
- 405 7. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and  
406 calcium phosphate product with mortality risk inchronic hemodialysis patients: a national  
407 study. *Am J Kidney Dis* 1998; 31: 607–617.
- 408 8. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity  
409 in maintenance hemodialysis. *J Am Soc Nephrol* 2004; 15: 2208–2218.
- 410 9. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca PO(4)  
411 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis  
412 patients. *J Am Soc Nephrol* 2001; 12: 2131–213
- 413 10. Stevens LADO, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid  
414 hormone levels in combination and as a function of dialysis duration predict mortality:  
415 evidence for the complexity of the association between mineral metabolism and utcomes.  
416 *J Am Soc Nephrol* 2004; 15: 770.

- 417 11. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and  
418 cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. *J*  
419 *Am Soc Nephrol* 2005; 16: 1788–1793.
- 420 12. Albuquerque RFC, Carbonara CEM, Martin RCT, Reis LM, Nascimento Jr CP, Arap SS,  
421 et al. Parathyroidectomy in patients with chronic kidney disease: Impacts of different  
422 techniques on the biochemical and clinical evolution of secondary hyperparathyroidism.  
423 *Surgery*. 2018;163(2):381-7
- 424 13. Campos SR, Gusmão MHL, Fortes A, Sampaio LR, Barreto JM. Estado nutricional e  
425 ingestão Estado nutricional e ingestão alimentar de pacientes em diálise peritoneal  
426 contínua com e sem hiperparatireoidismo secundário. *J Bras Nefrol*. 2012;34(2):170-7
- 427 14. Coelho DM, Castro ADM, Tavares HA, Abreu PBC, Glória RR, Duarte MH, et al.  
428 Efeitos de um Programa de Exercícios Físicos no Condicionamento de Pacientes em  
429 Hemodiálise. *J Bras Nefrol*. 2006;28(3):121-7.
- 430 15. Duarte J, Medeiros RF, Di Pietro T, Lopes TM. Alterações de volumes e capacidades  
431 pulmonares pré e pós-hemodiálise em insuficiência renal crônica TT Changes in lung  
432 volume and capacity before and after hemodialysis in chronic renal failure. *J Heal Sci*  
433 *Inst*. 2011;29(1):70-2
- 434 16. Fassbinder TRC, Winkelmann ER, Schneider J, Wendland J, Oliveira OB. Functional  
435 Capacity and Quality of Life in Patients with Chronic Kidney Disease In Pre-Dialytic  
436 Treatment and on Hemodialysis - A Cross sectional study. *J Bras Nefrol*. 2015;37(1):47-  
437 54

- 438 17. Maimoun, L., Lumbroso, S., Manetta, J., Paris, F., Leroux, J.L. and Sultan, C. (2003)  
439 Testosterone is significantly reduced in endurance athletes without impact on bone  
440 mineral density. *Hormone Research* 59, 285–292
- 441 18. Glastre, C., Braillon, P., David, L., Cochat, P., Meunier, P.J. and Delmas P.D. (1990)  
442 Measurement of bone mineral content of the lumbar spine by dual energy x-ray  
443 absorptiometry in normal children: correlations with growth parameters. *The Journal of*  
444 *Clinical Endocrinology and Metabolism* 70, 1330-1333.
- 445 19. Thorsen, K., Kristoffersson, A., Hultdin, J. and Lorentzon, R. (1997) Effects of moderate  
446 endurance exercise on calcium, parathyroid hormone, and markers of bone metabolism in  
447 young women. *Calcified Tissue International* 60, 16-20.
- 448 20. Brahm, H., Piehl-Aulin, K. and Ljunghall, S. (1997a) Bone metabolism during exercise  
449 and recovery: the influence of plasma volume and physical fitness. *Calcified Tissue*  
450 *International* 61, 192-198.
- 451 21. Ljunghall, S., Joborn, H., Roxin, L.E., Skarfors, E.T., Wide, L.E. and Lithell, H.O.  
452 (1988) Increase in serum parathyroid hormone levels after prolonged physical exercise.  
453 *Medicine and Science in Sports Exercise* 20, 122-125
- 454 22. Zerath, E., Holy, X., Douce, P., Guezennec, C.Y. and Chatard, J.C. (1997) Effect of  
455 endurance training on postexercise parathyroid hormone levels in elderly men. *Medicine*  
456 *and Science in Sports and Exercise* 29, 1139-1145.
- 457 23. Elshinnawy, H.A., Mohamed, A.M.B.B., Farrag, D.A.B. et al. Effect of intradialytic  
458 exercise on bone profile in hemodialysis patients. *Egypt Rheumatol Rehabil* 48, 24  
459 (2021).

- 460 24. Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of Renal Disease.  
461 Perm J. 2016 Summer;20(3):15-127. doi: 10.7812/TPP/15-127. Epub 2016 Jul 22.
- 462 25. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2017)  
463 KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention,  
464 and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney*  
465 *Int Suppl* 7:1–59. 2009;76(Suppl 113):S1-S130.
- 466 26. Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and  
467 association with outcomes among patients with secondary hyperparathyroidism on  
468 chronic hemodialysis: the DOPPS study. *Clin J Am Soc Nephrol*. 2015;10(1):98–109.
- 469 27. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a  
470 growing concern. *Kidney Int*. 2008;74(6):721–731.
- 471 28. Hruska KA, Choi ET, Memon I, Davis TK, Mathew S. Cardiovascular risk in chronic  
472 kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD) *Pediatr Nephrol*.  
473 2010;25(4):769–778.
- 474 29. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. *J Clin*  
475 *Invest*. 2011;121(11):4393–4408.
- 476 30. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism  
477 and disease treatment goals with cinacalcet HCl. *Kidney Int*. 2005;67(2):760–771.
- 478 31. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular  
479 disease in patients undergoing dialysis. *N Engl J Med*. 2012;367(26):2482–2494.
- 480 32. Bouassida A, Latiri I, Bouassida S, Zalleg D, Zaouali M, Feki Y, Gharbi N, Zbidi A,  
481 Tabka Z (2006) Parathyroid hormone and physical exercise: a brief review. *J Sports Sci*  
482 *Med* 5(3):367–374



- 483 33. Lombardi G, Ziemann E, Banfi G, Corbetta S (2020) Physical activity- dependent  
484 regulation of parathyroid hormone and calcium-phosphorous metabolism. *Int J Mol Sci*  
485 21(15):5388.
- 486 34. Makhloogh A, Ilali E, Mohseni R, Shahmohammadi S. Effect of intradialytic aerobic  
487 exercise on serum electrolytes levels in he- modialysis patients. *Iran J Kidney Dis.*  
488 2012;6(2):119–23.
- 489 35. Vaithilingam I, Polkinghorne KR, Atkins RC, Kerr PG. Time and exercise improve  
490 phosphate removal in hemodialysis patients. *Am J Kidney Dis.* 2004;43(1):85–9.
- 491 36. Borzou SR, Gholyaf M, Zandiha M, Amini R, Goodarzi MT, Torka- man B. The effect of  
492 increasing blood flow rate on dialysis adequacy in hemodialysis patients. *Saudi J Kidney*  
493 *Dis Transpl.* 2009;20(4):639–42.
- 494 37. Asadi Noghabi A, Bassampour SH, Zolfaghari M. Critical care nursing ICU, CCU,  
495 dialysis. Salemi publication; 2th ed. 2007; p. 448-53.
- 496 38. Cappy CS, Jablonka J, Schroeder ET. The effects of exercise during hemodialysis on  
497 physical performance and nutrition assessment. *J Ren Nutr.* 1999;9:63-70.
- 498 39. Salhab N, Alrukhaimi M, Kooman J, Fiaccadori E, Aljubori H, Rizk R, Karavetian M  
499 (2019) Effect of intradialytic exercise on hyperphosphatemia and malnutrition. *Nutrients*  
500 11(10):2464.
- 501 40. Cardoso, D.F., Marques, E.A., Leal, D.V. et al. Impact of physical activity and exercise  
502 on bone health in patients with chronic kidney disease: a systematic review of  
503 observational and experimental studies. *BMC Nephrol* 21, 334 (2020).

- 504 41. Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MW, Larsson L: Effect of  
505 chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. *Kidney*  
506 *Int* 60: 257–265, 2001
- 507 42. Torres PU. Bone alkaline phosphatase isoforms in chronic renal failure. *Kidney Int.*  
508 2002;61:1178–1179.
- 509 43. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts  
510 mortality among maintenance hemodialysis patients. *J Am Soc Nephrol.* 2008;19:2193–  
511 2203.
- 512 44. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC. Upregulation of alkaline  
513 phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular  
514 calcification. *Kidney Int.* 2008;73:1024–1030.
- 515 45. O'Neill WC. Pyrophosphate, alkaline phosphatase, and vascular calcification. *Circ Res.*  
516 2006;99:e2.
- 517 46. Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular  
518 calcification in renal failure? . *Kidney Int.* 2008;73:989–991.
- 519 47. Tonelli M, Curhan G, Pfeffer M, et al. Relation between alkaline phosphatase, serum  
520 phosphate, and all-cause or cardiovascular mortality. *Circulation.* 2009;120:1784–1792.
- 521 48. Park JC, Kovesdy CP, Duong U, Streja E, Rambod M, Nissenson AR, Sprague SM,  
522 Kalantar-Zadeh K. Association of serum alkaline phosphatase and bone mineral density  
523 in maintenance hemodialysis patients. *Hemodial Int.* 2010 Apr;14(2):182-92. doi:  
524 10.1111/j.1542-4758.2009.00430.x. Epub 2010 Mar 24.

- 525 49. Huang G-S, Chu T-S, Lou M-F, Hwang S-L, Yang R-S. Factors associated with low bone  
526 mass in the hemodialysis patients - a cross-sectional correlation study. *BMC*  
527 *Musculoskelet Disord.* 2009;10:60.
- 528 50. Ota S, Takahashi K, Tani K, Makino H. Bone metabolism and daily physical activity in  
529 women undergoing hemodialysis. *Nihon Jinzo Gakkai Shi.* 1997;39(4):441–6.
- 530 51. Gomes TS, Aioke DT, Baria FG, Gracioli FG, Moyses RMA, Cuppari L (2017) Effect of  
531 aerobic exercise on markers of bone metabolism of overweight and obese patients with  
532 chronic kidney disease. *J Ren Nutr* 27(5):364–371.
- 533 52. Rudberg A, Magnusson P, Larsson L, Joborn H. Serum isoforms of bone alkaline  
534 phosphatase increase during physical exercise in women. *Calcif Tissue Int.* 2000;66:  
535 342–347. pmid:10773103
- 536 53. Fragala MS, Bi C, Chaump M, Kaufman HW, Kroll MH (2017) Associations of aerobic  
537 and strength exercise with clinical laboratory test values. *PLOS ONE* 12(10): e0180840.
- 538 54. Frost HM. The mechanostat: a proposed pathogenic mechanism of osteoporoses and the  
539 bone mass effects of mechanical and nonmechanical agents. *Bone Miner.* 1987;2(2):73–  
540 85.
- 541 55. Frost HM. Bone’s mechanostat: a 2003 update. *Anat Rec A Discov Mol Cell Evol Biol.*  
542 2003;275(2):1081–1101.
- 543 56. Liao M-T, Liu W-C, Lin F-H, Huang C-F, Chen S-Y, Liu C-C, et al. Intradialytic aerobic  
544 cycling exercise alleviates inflammation and improves endothelial progenitor cell count  
545 and bone density in hemodialysis patients. *Medicine.*2016;95(27):e4134.